Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.56 |
| ▸ | DRD4 | P21917 | 5/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | DRD1 | P21728 | 4/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416496 | 1.00 | DRD2 (0.56) | DRD2CHRM1DRD4DRD3DRD1 | |
| Hydrochloric Acid SCHEMBL5445211 | 0.99 | DRD2 (0.55) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL4202572 | 0.87 | CYP1A2 (0.55) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL3688075 | 0.85 | DRD2 (0.51) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL23234145 | 0.83 | DRD2 (0.41) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL5936584 | 0.83 | CYP1A2 (0.51) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL4447696 | 0.81 | CHRM1 (0.52) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL11535134 | 0.79 | DRD2 (0.50) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL3858770 | 0.79 | CHRM1 (0.47) | DRD2CHRM1DRD4DRD3DRD1 | |
| SCHEMBL5936592 | 0.78 | CYP1A2 (0.46) | DRD2CHRM1DRD3DRD1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| US-7700587-B2 | Haloperidol analogs | FLORIDA A&M UNIVERSITY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060052363-A1 | which are incapable of metabolizing to BCPP+ like species, and have affinity for D2 receptor subtype and functions as dopamine receptor antagonist | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-09 | — | — | US | disclosed |
| US-20060039866-A1 | Method for treating sleep-related breathing disorders | CYPRESS BIOSCIENCE, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20050192273-A1 | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist | JOHNSON BRYAN G (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005013961-A1 | COMBINATION THERAPY FOR TREATMENT OF COGNITIVE DISORDERS OR PSYCHOSES | ELI LILLY AND COMPANY (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1492595-A1 | THERAPY FOR PSYCHOSES COMBINING AN ATYPICAL ANTIPSYCHOTIC AND AN MGLU2/3 RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040162355-A1 | Methods of treating and preventing cerebral function disorders using sibutramine metabolites | SEPRACOR INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2003084610-A1 | THERAPY FOR PSYCHOSES COMBINING AN ATYPICAL ANTIPSYCHOTIC AND AN MGLU2/3 RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | DRD2 1/4885CHRM1 131/4885DRD4 4/4885 |
| US-20040162355-A1 | Methods of treating and preventing cerebral function disorders using sibutramine metabolites | OPRL1, OPRM1, OPRK1 | DRD2 35/4885CHRM1 159/4885DRD4 174/4885 |
| US-20060052363-A1 | which are incapable of metabolizing to BCPP+ like species, and have affinity for D2 receptor subtype and functions as dopamine receptor antagonist | DBH, TACR1, PRLHR | DRD2 7/4885CHRM1 109/4885DRD4 89/4885 |
| US-20060039866-A1 | Method for treating sleep-related breathing disorders | DAZAP1, ZMYND8, CHAT | DRD2 461/4885CHRM1 374/4885DRD4 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.